Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

 Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Eisai and Purdue Report Result of Lemborexant in P-III SUNRISE 2 Study for Insomnia in Adults

Shots:

  • Numab to receive up front, research funding, success fees, milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules developed utilizing Numab’s MATCH platform
  • The focus of the agreement is to leverage Numab’s multi-specific technology to generate cancer therapies providing superior efficacy and safety as compared to benchmark immunotherapies
  • Numab is utilizing its Fv-stabilizing λcap technology and MATCH platform to generate multi-specific Ab with a plug-and-play novel mechanism with superior efficacy and favorable safety profiles

Click here to­ read full press release/ article | Ref: Businesswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post